Kaneka Corporation

Pathogenesis Corporation

Novartis Ag

Seattle Children's Hospital

Alan B Montgomery

David J Porubek

Lynn Massman Rose

Arnold L Smith

Bonnie W Ramsey

Donald Robert VanDevanter

A method for treatment of bacterial infections with rifalazil administered once-weekly, or twice-weekly. A method for treatment of tuberculosis caused by, infections caused bycomplex, infections caused byand infections caused byby administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Method for treatment of bacterial infections with once or twice-weekly administered rifalazil

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by , infections caused by complex, infections caused by and infections caused by by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by,, infections caused by,complex, infections caused by,and infections caused by,by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

A method for treatment, prevention and containment of acute and chronic tuberculosis using a preservative-free concentrated tobramycin aerosol formulation delivering tobramycin to the lung endobronchial space including alveoli in an aerosol having mass medium average diameter predominantly between 1 to 5.mu.. The method comprises administration of tobramycin in concentration one to ten thousand times higher than the minimal inhibitory concentration of Mycobacterium tuberculosis. A method for containment of and decreasing infectivity periods of tuberculosis patients to shorter periods of time.

Method and a tobramycin aerosol formulation for treatment prevention and

An anti-Pseudomonas aeruginosa agent which is substantially pure biologically active colistin, its component, a mixture thereof or a pharmaceutically acceptable salt thereof delivered as an aerosol or dry powder formulation. A formulation and method for preparation of substantially pure biologically active colistin, its components, mixtures thereof and a pharmaceutically acceptable salts thereof. A method for treatment and prophylaxis of Pseudomonas aeruginosa, Stenotrophomonas maltophilia or other susceptible pulmonary bacterial infections.

Pure biologically active colistin, its components and a colistin

An aminoglycoside formulation for delivery by aerosolization. The concentrated aminoglycoside formulation containing an efficacious amount of aminoglycoside able to inhibit 95-100% of susceptible bacteria. Aminoglycoside formulated in 5 ml solution of a quarter normal saline having pH between 5.5 and 6.5. The method for treatment of endobronchial infections by a produced by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5 .mu., produced by a jet or ultrasonic nebulizer.

Growing community of inventors

Bellevue, WA, United States of America

Alan B Montgomery